The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer.
 
Christopher Lemmon
No Relationships to Disclose
 
Gregory M.M. Videtic
Speakers' Bureau - AstraZeneca
 
Sudish C. Murthy
No Relationships to Disclose
 
Kevin L. Stephans
Honoraria - Astellas Pharma
 
Marc A. Shapiro
Consulting or Advisory Role - Anthem
 
Usman Ahmad
No Relationships to Disclose
 
Daniel Raymond
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Vamsidhar Velcheti
Consulting or Advisory Role - Alkermes; AstraZeneca/MedImmune; Boston Scientific; Bristol-Myers Squibb; Dr. Reddy's; Foundation Medicine; Genentech; Lilly; Merck; Nektar; Novartis
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Foundation Medicine; Merck
 
Alejandro Bribriesco
No Relationships to Disclose
 
Nathan A. Pennell
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cota Healthcare; Genentech; Inivata; Lilly; Merck; Regeneron
Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)